Galectin Therapeutics Statistics
Total Valuation
GALT has a market cap or net worth of $83.54 million. The enterprise value is $184.54 million.
Important Dates
The last earnings date was Thursday, May 15, 2025, before market open.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GALT has 63.29 million shares outstanding. The number of shares has increased by 3.02% in one year.
| Current Share Class | 63.29M |
| Shares Outstanding | 63.29M |
| Shares Change (YoY) | +3.02% |
| Shares Change (QoQ) | +0.73% |
| Owned by Insiders (%) | 20.54% |
| Owned by Institutions (%) | 15.78% |
| Float | 44.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.08
| Current Ratio | 0.08 |
| Quick Ratio | 0.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.53 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -143.58% |
| Return on Invested Capital (ROIC) | -536.87% |
| Return on Capital Employed (ROCE) | 40.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.02M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.82% in the last 52 weeks. The beta is 0.54, so GALT's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -51.82% |
| 50-Day Moving Average | 1.33 |
| 200-Day Moving Average | 1.88 |
| Relative Strength Index (RSI) | 50.23 |
| Average Volume (20 Days) | 164,340 |
Short Selling Information
The latest short interest is 8.67 million, so 13.69% of the outstanding shares have been sold short.
| Short Interest | 8.67M |
| Short Previous Month | 8.47M |
| Short % of Shares Out | 13.69% |
| Short % of Float | 19.64% |
| Short Ratio (days to cover) | 62.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -40.68M |
| Pretax Income | -44.65M |
| Net Income | -45.31M |
| EBITDA | n/a |
| EBIT | -40.68M |
| Earnings Per Share (EPS) | -$0.72 |
Full Income StatementBalance Sheet
The company has $7.43 million in cash and $108.43 million in debt, giving a net cash position of -$101.00 million or -$1.60 per share.
| Cash & Cash Equivalents | 7.43M |
| Total Debt | 108.43M |
| Net Cash | -101.00M |
| Net Cash Per Share | -$1.60 |
| Equity (Book Value) | -112.26M |
| Book Value Per Share | -1.81 |
| Working Capital | -101.56M |
Full Balance SheetCash Flow
| Operating Cash Flow | -37.35M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |